InMed Pharmaceuticals to Present at the Regulatory Affairs Professionals Society's annual conference

VANCOUVER, Sept. 23, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today announced that Karen Long, InMed's Senior Director, Drug Development, will be presenting at the Regulatory Affairs Professionals Society's annual conference at the Philadelphia Convention Center in Philadelphia, 21-24 September 2019.

InMed Pharmaceuticals Inc. (CNW Group/InMed Pharmaceuticals Inc.)

Karen Long, MSc, RAC will participate on a panel on Tuesday, September 24th at 10:30 am EST titled "Cannabinoids: Therapeutic Applications and Regulatory Pathways."  The Regulatory Affairs Professionals Society (RAPS) is the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products.

Karen has 25 years of regulatory affairs experience in the drug and medical device industries, specializing in novel drug delivery systems such as liposomes and biodegradable polymers. She holds a Bachelor of Science in Chemistry and a Master's degree in Pharmaceutical Science from the University of British Columbia, and has Regulatory Affairs Certification (RAC) for United States, European, Canadian and Global regulatory affairs.

For more information on the conference, please visit www.raps.org/convergence-2019/home.

About InMed:
InMed Pharmaceuticals is a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids, as well as a pipeline of medications that target diseases with high unmet medical needs.  For more information, visit www.inmedpharma.com.

Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws.  Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  Forward-looking information in this news release includes statements about: developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs; and Karen Long participating in the RAPS annual conference as a speaker.

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: Karen Long's continued availability to participate in the RAPS annual conference; continued and timely positive preclinical and clinical efficacy data; the speed of regulatory approvals; demand for InMed's products; and continued economic and market stability.  While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.  Known risk factors include, among others: the RAPS annual conference presentation may not occur as planned, or at all; clinical trials may not proceed as anticipated; economic or market conditions may worsen; and InMed's proprietary biosynthesis manufacturing process and drug development programs may not deliver the expected level of results.  A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed's most recent Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE InMed Pharmaceuticals Inc.

For further information: Investor Contact: InMed Pharmaceuticals Inc., Bruce Colwill, Chief Financial Officer, T: +1.604.669.7207, E: bcolwill@inmedpharma.com; Edison Advisors for InMed Pharmaceuticals: Joe Green, Senior Vice President, T: +1.646.653.7030, E: jgreen@edisongroup.com